The company is letting go of 150 staffers alongside a decision to officially terminate the high-profile program, which was acquired in 2016.

The company will stop developing five experimental treatments, including two oral checkpoint inhibitors targeting PD-L1.

The collaboration between Lynx.MD and Schweiger Dermatology Group marks a significant leap forward in dermatological research, paving the way for meaningful improvements in patient care and treatment ...

BALTIMORE, MD, July 30, 2024 — Sapio Sciences, the science-awareTM lab informatics platform, and Zifo, the leading scientific informatics services company today announced a strategic partnership to ...

The study is the latest test of a class of cholesterol medicines known as CETP inhibitors, which were abandoned by several large drugmakers last decade.

The pharma company will pay up to $1.3 billion to acquire San Diego-based Nerio and its research into novel immune checkpoint inhibitors.

The deal resembles recent Flagship alliances with Pfizer and Novo Nordisk, allowing the British pharma to comb through the company creator’s portfolio to unearth up to 10 therapies.

Some analysts described Sanofi’s pipeline of immune system therapies, which includes more than half a dozen drugs in mid- to late-stage testing, as “underappreciated” by investors, as sales of ...

The drug’s advancement continued what one analyst described as a “torrid” pace for Viking’s closely watched medicine, which started human testing in 2022 and could reach a Phase 3 trial next year.

The company claimed “higher than anticipated” scores from trial volunteers on placebo led to the disappointing data, prompting it to halt internal trials.

CEO Thomas Schinecker claimed the company has “many opportunities” to stand out in the competitive field, and can get to market “much faster” than investors expect.

Autobahn’s lead candidate is designed to stimulate thyroid hormone receptors as a way to complement existing antidepressants.